Acurx Pharmaceuticals, Inc. — FY 2022 Form 10-K
Reporting period: Year ended December 31, 2022. This is an annual filing; it does not provide a clear standalone fourth-quarter financial results table.
Business context
Acurx is a clinical-stage biotechnology company with no approved products or product revenue. Its lead candidate, ibezapolstat, is being developed for Clostridioides difficile infection (CDI); its Phase 2b trial compares the candidate with vancomycin. The early-stage ACX-375C program targets other Gram-positive infections, including MRSA and VRE.
Financial results and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $4.75 million | $2.03 million |
| General and administrative expense | $7.34 million | $10.78 million |
| Total operating expenses | $12.09 million | $12.81 million |
| Net loss | $12.09 million | $12.75 million |
| Basic and diluted loss per share | $1.12 | $1.49 |
| Net cash used in operating activities | $7.54 million | $5.01 million |
| Net cash from financing activities | $3.70 million | $14.80 million |
| Cash at year-end | $9.11 million | $12.96 million |
At December 31, 2022, working capital was approximately $7.3 million; total assets were $9.38 million and total liabilities were $2.06 million, primarily accounts payable and accrued expenses. The filing reports no outstanding borrowings; its prior $66,503 PPP loan was fully forgiven in 2021. Profit margins are not meaningful because the company has no revenue.
The auditor reported substantial doubt about Acurx’s ability to continue as a going concern. Management stated that existing cash was not expected to fund anticipated operations for at least 12 months from issuance of the financial statements. Acurx has relied on equity financing and expects to seek further funding.
Changes versus prior year
- R&D expense rose 134%, primarily from higher consulting costs for the Phase 2b trial.
- G&A expense fell 32%, mainly due to lower professional fees and share-based compensation.
- Net loss narrowed by approximately $0.65 million, while operating cash use increased by approximately $2.53 million.
- Cash declined by approximately $3.85 million. The 2022 registered direct offering and concurrent private placement generated approximately $3.70 million net, compared with $14.80 million of net IPO proceeds in 2021.
- Year-end common shares outstanding increased to 11.63 million from 10.22 million. The company also reported 4.22 million warrants and 2.47 million stock options outstanding at year-end.
Outlook, developments and risks
- Clinical program: The Phase 2a trial was stopped after 10 patients; all 10 met reported clinical-cure and sustained-cure endpoints, with no treatment-related serious adverse events reported. This small, early-stage study does not establish results in larger trials.
- Phase 2b: In January 2023, Acurx sought FDA permission for an independent data monitoring committee to review interim data after 36 patients. At the filing date, 25 patients had been enrolled. The committee would recommend whether to stop early or continue enrollment; the company said it intended to report available data after review. The filing gives no Phase 2b outcome.
- Financing and dilution: Additional capital is needed, but funding may not be available on acceptable terms. The 2022 financing included warrants, and further equity financing could dilute shareholders. Warrants and options are potential sources of additional dilution.
- Execution risks: Development depends on clinical-trial enrollment and outcomes, FDA approval, third-party manufacturers and service providers, and protection of intellectual property. The company relies on a major vendor for a substantial share of R&D spending and has no backup drug-substance supplier in place.
- Commercial outlook: No near-term product revenue or formal financial guidance is provided. Management’s market-size and peak-sales figures are estimates contingent on clinical success, approval, pricing, reimbursement and market acceptance.
- Other disclosures: Acurx reported that its disclosure controls and internal control over financial reporting were effective at year-end 2022 and that a prior segregation-of-duties weakness had been remediated. The auditor did not provide an internal-control attestation. No material litigation was reported.
Important facts for investors to verify
- Current cash runway, subsequent financing, and the company’s plans to address the going-concern uncertainty.
- FDA acceptance of the proposed interim review, the monitoring committee’s recommendation, enrollment progress and final Phase 2b results.
- Clinical-trial costs and whether additional Phase 3 trials are required, including their expected size and funding needs.
- Outstanding warrants and options, exercise terms, subsequent exercises or issuances, and resulting fully diluted share count.
- Manufacturing supply continuity, vendor concentration, and regulatory and commercial assumptions underlying management’s market estimates.